Using a special dye to detect lung cancer during surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I/II trial investigates the optimal dose and timing of panitumumab-IRDye800, a combination of an antibody drug and an investigational dye, to enhance the visibility of lung cancer during surgical procedures. The study aims to compare the effectiveness of this dye in identifying tumor cells versus normal tissue using near-infrared fluorescence imaging. Participants will receive the dye intravenously before undergoing surgery, and the study will assess both the safety of the dye and its ability to detect primary tumors and positive lymph nodes. Follow-up will occur for up to 30 days post-treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with lung nodule or mass concerning for malignancy, either primary lung cancer or lung metastases, whether or not it is biopsy-proven
* Patients scheduled to undergo planned standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent for lung cancer
* Karnofsky performance status of at least 70% or Eastern Cooperative Oncology Group (ECOG)/Zubrod level 0-2
* Hemoglobin ≥ 9 gm/dL
* White blood cell count \> 3000/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Serum creatinine ≤ 1.5 times upper reference range

Exclusion Criteria:

* Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
* History of infusion reactions to monoclonal antibody therapies
* Pregnant or breastfeeding
* Magnesium or potassium lower than the normal institutional values
* Subjects receiving class IA (quinidine, procanamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
* Prisoners, institutionalized individuals, and patients unable to consent for themselves

Where it's running

• Stanford University, School of Medicine
  Palo Alto, California, United States Recruiting

Study contacts

• Principal investigator: Natalie Lui — Stanford University
• Study coordinator: Natalie Lui
• Email: natalielui@stanford.edu
• Phone: 650-721-2086

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining low-dose interleukin-2 and pembrolizumab for advanced lung cancer treatment

  This study is testing a new combination of low-dose interleukin-2 and pembrolizumab to see if it can help people with untreated stage IV non-small cell lung cancer fight their disease better.

  Recruiting Early Phase 1 Emory University · Atlanta, Georgia · NCT05493566

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Combining PBF-1129 and Nivolumab for Advanced Lung Cancer Treatment

  This study is testing a new combination of two drugs, PBF-1129 and nivolumab, to see if it can help people with advanced lung cancer live longer and feel better.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05234307

• Using temozolomide and atezolizumab for advanced small cell lung cancer

  This study is testing if a combination of two drugs, temozolomide and atezolizumab, can help people with advanced small cell lung cancer live longer and feel better.

  Recruiting at 5 sites Phase 2 Big Ten Cancer Research Consortium · Chicago, Illinois and 4 other locations · NCT04919382

• Combining osimertinib and tegavivint for treating metastatic EGFR-mutant lung cancer

  This study is testing a new combination of two drugs, osimertinib and tegavivint, to see if it can help people with advanced lung cancer caused by EGFR mutations feel better and live longer.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT04780568

• Avapritinib for treating advanced solid tumors with specific mutations

  This study is testing if a new drug called avapritinib can help people with advanced solid tumors that have specific mutations feel better and live longer after other treatments haven't worked.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04771520

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.